The Same Molecule, Two Approvals
Tirzepatide was first approved in 2022 as Mounjaro — specifically for the management of blood sugar in adults with type 2 diabetes. In 2023, Eli Lilly received a second FDA approval for the same molecule at higher doses, marketed as Zepbound, for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
The pharmacology is identical. What differs is the approved indication, the labeled dose ceiling, and the insurance and prescribing pathway that comes with each brand. Mounjaro tops out at 15 mg weekly under its diabetes label. Zepbound is approved up to 15 mg weekly as well but under the weight management indication — making it the on-label choice for patients seeking tirzepatide specifically for weight loss without a diabetes diagnosis.
Why Mounjaro Became a Weight Loss Drug Anyway
Before Zepbound existed, physicians commonly prescribed Mounjaro off-label for weight loss in patients without a diabetes diagnosis. The trial data supporting tirzepatide for weight management was unambiguous — and patients who could access Mounjaro at commercial pricing or through manufacturer savings programs were using it for that purpose well before Zepbound was approved.
This mirrors the Ozempic/Wegovy dynamic: a molecule approved for diabetes demonstrating such compelling weight loss outcomes that a separate weight management approval was pursued and granted. The clinical mechanism is the same product in both cases.
"The drug does not know which label it carries. The distinction between Mounjaro and Zepbound is regulatory and commercial — not pharmacological. The molecule produces the same outcomes either way."
Access and Cost Reality
Brand-name Zepbound and Mounjaro both carry list prices in the range of $1,000 to $1,300 per month before insurance. Manufacturer savings cards exist for both but carry eligibility restrictions. Insurance coverage for Zepbound under weight management indications is inconsistent — many commercial plans exclude GLP-1 drugs for weight loss even where the FDA indication exists.
Compounded tirzepatide access exists but is more limited and more variable than compounded semaglutide. The regulatory status of compounded tirzepatide has fluctuated with FDA shortage determinations. A licensed provider can advise on current availability and candidacy at the time of consultation.
Physician-supervised consultation.
Current availability determined at intake.
Which One Should You Ask About?
If you have type 2 diabetes and your insurance covers Mounjaro, that is a straightforward path. If you are seeking tirzepatide specifically for weight loss without a diabetes diagnosis, Zepbound is the on-label option — though coverage varies significantly. If brand-name pricing is prohibitive, a conversation with a licensed telehealth provider about compounded tirzepatide availability is worth having.
The most important variable is not the brand name. It is whether the product you are using comes from a properly regulated source, under physician supervision, with a titration schedule matched to your response.